Biogen Names Christopher Viehbacher New CEO
Christopher Viehbacher is a former chief executive of French pharmaceutical company Sanofi.
Photo:
ROMUALD MEIGNEUX/SIPA/Associated Press
Biogen Inc.
named veteran pharmaceutical executive
Christopher Viehbacher
president and chief executive on Thursday, capping a monthslong search for a new leader after the failed launch of its once-promising Alzheimer’s disease drug Aduhelm.
Mr. Viehbacher, who will also join the board, succeeds
Michel Vounatsos,
who has led Biogen since 2017 and in May said he would resign. The Cambridge, Mass., company has worked to chart a new course following Medicare’s refusal to cover its new Alzheimer’s drug Aduhelm.
Mr. Viehbacher, 62 years, spent six years at the helm of French pharmaceutical company
Sanofi SA
before being ousted in late 2014 amid clashes with the board.
Mr. Viehbacher, who also spent two decades with
GlaxoSmithKline
(now
GSK
PLC), in 2015 co-founded healthcare investment fund Gurnet Point Capital and most recently served as managing partner, Biogen said.
The company said Mr. Viehbacher would receive an annualized base salary of $1.6 million and would be eligible for an annual bonus with a target of 150% of his pay.
Biogen said Mr. Vounatsos would remain an employee for a limited period to assist with the transition.
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Christopher Viehbacher is a former chief executive of French pharmaceutical company Sanofi.
Photo:
ROMUALD MEIGNEUX/SIPA/Associated Press
Biogen Inc.
named veteran pharmaceutical executive
Christopher Viehbacher
president and chief executive on Thursday, capping a monthslong search for a new leader after the failed launch of its once-promising Alzheimer’s disease drug Aduhelm.
Mr. Viehbacher, who will also join the board, succeeds
Michel Vounatsos,
who has led Biogen since 2017 and in May said he would resign. The Cambridge, Mass., company has worked to chart a new course following Medicare’s refusal to cover its new Alzheimer’s drug Aduhelm.
Mr. Viehbacher, 62 years, spent six years at the helm of French pharmaceutical company
Sanofi SA
before being ousted in late 2014 amid clashes with the board.
Mr. Viehbacher, who also spent two decades with
GlaxoSmithKline
(now
GSK
PLC), in 2015 co-founded healthcare investment fund Gurnet Point Capital and most recently served as managing partner, Biogen said.
The company said Mr. Viehbacher would receive an annualized base salary of $1.6 million and would be eligible for an annual bonus with a target of 150% of his pay.
Biogen said Mr. Vounatsos would remain an employee for a limited period to assist with the transition.
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.